In agreement with the upregulation of MHC, we also observed a strong enrichment in interferon signaling for effective tumor-suppressing treatments, particularly for NT GSDMD + IL-12, as well as for ineffective NT GSDMD + IL-1β + IL-18 treatment (Fig. 6c and Supplementary Fig. 9b), although not necessarily with the same genes. This evidence concerns the gene IL18 and neoplasm.